Russia invading Ukraine, global supply chain disruptions, energy shortages in Europe and widespread inflation worries have created a perfect storm in which investors naturally gravitate towards less riskier opportunities than biopharma.
In line with this shift in investor sentiment, the US XBI biotech index decreased by a further 28% during 2022, deepening the losses that happened during the latter part of...
About The Authors
Markus Thunecke, PhD (markus.thunecke@catenion.com), is a founding Senior Partner of Catenion, a biopharma focused strategy consulting firm. Erika Kuchen, PhD, is a Manager at Catenion (erika.kuchen@catenion.com), Alexander...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?